Abstract
Tumours exhibit higher basal levels of reactive oxygen species (ROS) and altered redox environment compared to normal cells. Excessive level of ROS can be toxic to these cells, thus they become more vulnerable to damage by further ROS insults induced by pharmacological agents. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Therefore, abrogation of such drugresistant mechanisms by redox modulation could have significant therapeutic implications. Many redox-modulating agents have been developed. The redox-active system epitomised by ascorbate-driven quinone redox cycling, and the group of redox-silent vitamin E analogues represented by α-tocopheryl succinate have been shown to induce selective cancer cell death in different types of cancer. These compounds synergistically act by destabilising organelles like mitochondria, unleashing their apoptogenic potential, which results in efficient death of malignant cells and suppression of tumour growth. Consistent with this notion, clinical trials that aim to examine the therapeutic performance of novel redoxmodulating drugs in cancer patients are currently under way.
Keywords: Apoptosis, autophagy, redox-active agents, redox-silent agent, ROS-based cancer therapy, vitamin E analogues.
Current Medicinal Chemistry
Title:Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Volume: 22 Issue: 5
Author(s): M. Tomasetti, L. Santarelli, R. Alleva, Lan-Feng Dong and J. Neuzil
Affiliation:
Keywords: Apoptosis, autophagy, redox-active agents, redox-silent agent, ROS-based cancer therapy, vitamin E analogues.
Abstract: Tumours exhibit higher basal levels of reactive oxygen species (ROS) and altered redox environment compared to normal cells. Excessive level of ROS can be toxic to these cells, thus they become more vulnerable to damage by further ROS insults induced by pharmacological agents. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Therefore, abrogation of such drugresistant mechanisms by redox modulation could have significant therapeutic implications. Many redox-modulating agents have been developed. The redox-active system epitomised by ascorbate-driven quinone redox cycling, and the group of redox-silent vitamin E analogues represented by α-tocopheryl succinate have been shown to induce selective cancer cell death in different types of cancer. These compounds synergistically act by destabilising organelles like mitochondria, unleashing their apoptogenic potential, which results in efficient death of malignant cells and suppression of tumour growth. Consistent with this notion, clinical trials that aim to examine the therapeutic performance of novel redoxmodulating drugs in cancer patients are currently under way.
Export Options
About this article
Cite this article as:
Tomasetti M., Santarelli L., Alleva R., Dong Lan-Feng and Neuzil J., Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer, Current Medicinal Chemistry 2015; 22 (5) . https://dx.doi.org/10.2174/0929867321666140915142219
DOI https://dx.doi.org/10.2174/0929867321666140915142219 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Looking out for Cancer Stem Cells’ Properties: The Value-Driving Role of CD44 for Personalized Medicines
Current Cancer Drug Targets Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer
Current Medicinal Chemistry The Blood-Brain Barrier: Its Influence in the Treatment of Brain Tumors Metastases
Current Cancer Drug Targets Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Recent Nanocarrier Approaches for Targeted Drug Delivery in Cancer Therapy
Current Molecular Pharmacology Aquaporins and Roles in Brain Health and Brain Injury
Mini-Reviews in Medicinal Chemistry Drug Tissue Distribution: Study Methods and Therapeutic Implications
Current Pharmaceutical Design Pharmacological Applications of Antioxidants: Lights and Shadows
Current Drug Targets Mesenchymal Stem Cells: An Emerging Tool for Cancer Targeting and Therapy
Current Stem Cell Research & Therapy 5-Lipoxygenase in the Central Nervous System: Therapeutic Implications
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Current Pharmaceutical Design Matrix Metalloproteinases: New Routes to the Use of MT1-MMP As A Therapeutic Target in Angiogenesis-Related Disease
Current Pharmaceutical Design Glycogen Metabolism and Brain Pathologies
Central Nervous System Agents in Medicinal Chemistry Measles Virus as An Oncolytic Vector Platform
Current Gene Therapy Mammalian Target of Rapamycin (mTOR) Inhibitors as Anti-Cancer Agents
Current Cancer Drug Targets Antitumor Effect of Butanoylated Heparin with Low Anticoagulant Activity on Lung Cancer Growth in Mice and Rats
Current Cancer Drug Targets Pleiotropic Role of HSF1 in Neoplastic Transformation
Current Cancer Drug Targets Imaging Malignant Gliomas with 99mTc-MIBI Brain Single-Photon Emission Computed Tomography
Current Medical Imaging Role of EGFR Monoclonal Antibodies in the Management of Non–small Cell Lung Cancer
Current Cancer Drug Targets The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals